Answers are grounded in this paper and cite their sources.
Introduction. Amidines have a fairly high biological activity. One aspect of their therapeutic action is the anti-inflammatory effect. Therefore, the development of a granulate technology based on amidines with anti-inflammatory activity for subsequent dosing into enteric capsules is an issue of interest today. Aim. To develop a granulate based on amidines with anti-inflammatory activity for subsequent dosing into enteric capsules. Materials and methods. An experimentally synthesized substance N-(naphthalene-2-yl)benzene carboximid¬amide and excipients: lactose monohydrate, sodium starch glycolate (Explotab®), povidone (Plasdone™ K-29/32) were used as the active substance. The granulate was obtained by pressing wet masses through. The resulting granulate was dosed into enteric capsules. The technological properties of the substance and the quality attributes of the granulate and capsules were determined according to the methods described in the State Pharmacopoeia of the Russian Federation, edition XIV (SP XIV). Results. According to the results of the study of technological properties, it was found that the substance has poor flowability, is quite light and bulky, the main fraction of the powder is particles up to 0.1 mm in size. To improve the flowability and reduce the hygroscopicity of the granulated material, lactose monohydrate was used as a filler. A 5% solution of Plasdone K-29/32 was chosen as a binder, which improves the dissolution and bioavailability of drugs due to the formation of water-soluble complexes. Sodium starch glycolate was used as a disintegrant. The resulting granulate was dosed into enteric capsules that meet the SP XIV requirements. Conclusion. A synthesis method was proposed and a substance of N-(naphthalene-2-yl)benzene carboximidamide with pharmacological activity was synthesized. Excipients were selected taking into account the properties of the substance, composition and technology of the granulate based on the previously synthesized substance N-(naphthalene-2-yl)benzene carboximidamide was developed, followed by dosing into enteric capsules, a draft specification for enteric capsules was proposed in accordance with the SP XIV requirements.
No takes yet. Share an insight, caveat, or question.
Mar’yushkina et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: